Alaunos Therapeutics

5 trials changed in the last 30 days: 0 stopped, 5 with notable changes, 0 with minor changes only.

1. Notable

   PICASSO · Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin…PICASSO · Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

   Reclassified as terminated (was completed)

   Alaunos Therapeutics·Phase 2· NCT00718484· Registry history of NCT00718484 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

2. Notable

   Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

   Reclassified as terminated (was completed)

   Alaunos Therapeutics·Phase 2· NCT00423306· Registry history of NCT00423306 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

3. Notable

   ZIO-101 in Advanced Blood and Bone Marrow Cancers

   Reclassified as terminated (was completed)

   Alaunos Therapeutics·Phase 2· NCT00421213· Registry history of NCT00421213 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

4. Notable

   Novel Indibulin Dosing Schedule · Metastatic Breast Cancer

   Reclassified as terminated (was completed)

   Alaunos Therapeutics·Phase 1· NCT01113970· Registry history of NCT01113970 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

5. Notable

   Indibulin in Combination With Capecitabine in Advanced Solid Tumors

   Reclassified as terminated (was completed)

   Alaunos Therapeutics·Phase 1· NCT00726687· Registry history of NCT00726687 on ClinicalTrials.gov (opens the registry)

   Sep 30, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.